Connect with us

HealthNews

Thermo Fisher will sell microbiology division to Astorg PE firm for over $1 Billion


Bengaluru – Medical equipment maker Thermo Fisher Scientific announced on Monday that it would be selling its microbiology division to Astorg private equity firm, for proximately $1.08 billion. The microbiology unit supplies culture media and antimicrobial susceptibility test products for pharmaceutical, clinical and food safety purposes. The unit is a part Thermo Fisher’s specialty diagnostics division and will generate $645 million of revenue by 2025. The transaction is a reflection of our active management in the company, and it provides us with more cital that we can use to create value for shareholders,” Marc Casper said, Thermo Fisher CEO. Thermo expects that the transaction will close in 2026’s second half. Thermo Fisher estimates that the deal will dilute the adjusted earnings per shares by $0.15 for the first full fiscal year following the closing. The company stated that it would give details about the impact on its 2026 outlook during its second-quarter earnings call.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)

Published r 28, 2026 06:33 AM IST

Join our community of over 2 million industry professionals. Subscribe to our Newsletter for the latest industry insights and analysis.

You can now get all the information about ETHealthworld on your mobile!

Up Next

ET has multiple sources that confirm Siemens Healthineers’ intention to exit American Oncology Institute in Hyderabad. The hospital chain is valued at around Rs 1,500-2,000 crore. Siemens has been advised on the deal by Alvarez & Marsal Investment Bank. The sources cited said several private equity firms have been approached. Healthcare Global Enterprises (HCG), a KKR backed listed cancer care network, has also been sounded as a bidder. The sale could be part of a broader discussion about Siemens Healthineers’ strategic direction. Bloomberg reported in 2013 that the company was in preliminary talks with major private-equity firms, such as Blackstone, CVC Capital Partners or KKR about a possible deal to sell its global diagnostics division. This could have been worth over $6 billion. Cancer Treatment Services International operated AOI, founded in 2012 by a team of doctors and industry professionals. CTSI was purchased by Varian Medical Systems from TPG Growth in 2019. Siemens Healthineers will acquire Varian in 2021 and bring AOI into its portfolio. According to sources, Siemens views AOI as a non core asset and has no plans to continue operating it in India. Both Siemens and HCG declined comment on this development. Siemens Healthineers focuses primarily on diagnostic imaging (including MRIs and CT scans), lab diagnostics, therapeutic images, and digital solutions. The company operates two production facilities in India – one for diagnostics in Vadodara and another for medical imaging in Bengaluru.

Continue Reading

HealthNews

Blue Machines AI & Cartesia Partner Up to Offer India Resident Voice AI Solutions.


New Delhi, India: Blue Machines AI & Cartesia announced a strategic partnership to deliver India resident, low latency conversational Voice AI Solutions for Enterprises. Initial focus is on regulated sectors like banking, insurance, financial services (BFSI), and healthcare. The companies stated that the collaboration is aimed at addressing two key priorities as Indian enterprises transition from pilot projects to full scale deployment of conversational AI – natural multilingual voice experience and India-resident processing in line with regulatory requirements. In the partnership, enterprises can deploy intelligent voice agents that are cable of understanding and executing complex business workflows. They will also be able integrate existing enterprise systems with low latency, as well as respond in multiple languages. The solution combines advanced voice technologies with real-time orchestration to provide scalable and context-aware solutions.

According to the companies, India-resident data processing will help enterprises meet regulatory requirements for governance, auditability and compliance, especially in highly regulated industries. The solution is available in multiple Indian languages including Tamil, Telugu and Kannada. It allows for hyper-localised customer service, onboarding and collection. The platform supports the deployment of voice agents on telephony as well as digital platforms. It allows for real-time voice generation and intelligent workflow execution, which reduces response times and maintains consistent voice quality even during high-volume interaction. Enterprises have the choice of either on-premises or cloud-hosted implementations. Blue Machines AI Voice AI Stack manages call lifecycles from beginning to end, including integration with CRM systems, banking software, internal Is and real-time streaming audio. Cartesia’s conversational AI model is built for Indian language speech processing, hyper-realistic voice production, and streaming responses to ensure a smooth flow of conversation, even when interrupted. Cartesia Co-Founder Arjun Desai said that enterprises want voice experiences which are natural and fast without compromising control or reliability. He said that Cartesia powers millions of voice interactions daily for global customers, and is strengthening their commitment to the Indian Market through its new Bengaluru Office. Nirmit parikh, CEO and founder of Blue Machines AI said that regional language support and compliance are essential for Indian companies. He said that the partnership allows organisations to deploy India resident, multilingual Voice AI Workflows with the performance and governance required in regulated industry. The companies have announced plans to add support for more Indian languages, create new enterprise workflows and work together on model improvements in order to accelerate deployment and drive measurable business results for enterprises that adopt Voice AI.


Published on Feb 20, 2026, at 5:17 PM (IST)

Join our community of over 2M+ professionals in the industry. Subscribe to the Newsletter to receive latest insights and analysis directly to your inbox.

You can now get all the information about ETHealthworld on your mobile!

Continue Reading

HealthNews

Financial strain on Bihar hospitals as they wait for Ayushman payments for months


Patna – Hospitals in Bihar empanelled with the Ayushman scheme have been waiting for reimbursement for over four months. This has caused financial stress to several charitable and private institutions that provide cashless treatment for poor patients. According to the rules of the Ayushman Bharat scheme, hospitals must clear their bills within 15 days when no questions are raised. Hospital administrators claimed that payment amounts in the millions of rupees are still pending, and have been since January. This has severely affected routine operations.

A number of hospitals have said that delayed reimbursements are making it hard to manage expenses such as staff salaries, medicine, equipment and other operational costs. Mahavir Cancer Hospital Director Dr Biswajit Snayal stated that the hospital owed more than 20 crore rupees, although recent payments have been made. Mahavir Vatsalya Aspatal – another hospital run by Mahavir Mandir Nayas Samiti, dedicated to child health care – is also experiencing the problem. The director of the hospital, Dr Rajeev Rajan Prasad, said that claims dating back to last January totaling nearly Rs 4 crore were still outstanding.

Ayushman Bharat (the government’s flagship healthcare insurance scheme) allows eligible beneficiaries cashless treatment in hospitals that are accredited. It is a big help to those with lower incomes. Rajeev stated that strengthening such schemes and timely payments will help to treat the poor. Many private hospitals in Patna have also complained about long delays in clearing bills, although many refused to name them.

Ruban Medical Center claimed that the hospital’s dues, which totaled around Rs 3 crore, had been pending for almost five months. Amit Kumar, the hospital’s public relations officer, said that the hospital had not yet received the payment.

Buddha Cancer Centre said that bills totaling nearly Rs 3 crore for around 1,100 cases awaited clearance. Director Dr Ridu Kumar said that bills for 1,100 cases were pending. Some of them have been awaiting clearance since January. Shashank Sinha, chief executive officer and special secretary of the Bihar Ayushman Bharat, acknowledged that there have been delays with bill clearances since March. He said that the process will resume in the next few weeks. Ayushman Bharat has been empanelled in 1,298 Bihar hospitals, 434 government and 864 privately owned.


Published on May 14, 2026, at 7:51 AM (IST)

Join our community of over 2 million industry professionals. Subscribe to our Newsletter for the latest industry insights and analysis.

You can now get all the information about ETHealthworld on your mobile!

HealthNews

India releases MANAS 1: AI trained using 60,000 hours worth of brainwave recordings aims to detect disorders as early as possible


New Delhi : Artificial intelligence could soon help doctors “read the brain” before disease is visible. A team of Indian scientists has developed MANAS 1, the Brain Language Foundation Model based on recordings of over 25,000 brainwaves. This model is designed to enable earlier detection of neurological disorders and psychiatric disorders. The model, developed by Intellihealth, led by Dr Puneet agarwal (former Professor at All India Institutes of Medical Sciences) and his team and launched by Hugging Face during an AI Summit, was created by Intellihealth. The Indian AI Mission of Ministry of Electronics and Information Technology funded the project with computational resources. MANAS 1 has been trained, unlike other AI systems to interpret EEG (electrical activity) signals. The 400 million parameters it contains are described by its creators as a foundation platform for developing AI tools that target specific diseases. The MANAS 1 model, which is similar to ChatGPT in concept, was developed by Dr Agarwal to help “understand the language of the brain.” This foundation model learns to interpret brain signals from large-scale EEG datasets that can’t be fully decoded using traditional tests like MRI. He said that the model provides a foundation on which AI tools to treat epilepsy and dementia, as well as other disorders, can be later built. It also helps researchers understand aspects of brain function, which are still poorly understood. The public health argument revolves around early access. India is facing a neurology and psychiatrist shortage, especially outside of major cities. The brain disorders are detected late and can lead to increased disability as well as long-term costs. Developers say that tools developed on MANAS 1 can assist doctors in Ayushman Arogya Mandirs and community health centres, as well as district hospitals and district hospitals with preliminary screening and timely referral. Before clinical deployment, any AI model that is disease-specific and derived from this platform will need to be proved by regulatory agencies. If such systems are validated at a scale, they could help reduce gs between symptom onsets and diagnoses — an important factor in conditions such epilepsy or dementia. MANAS 2 is the next-generation system, and it’s expected to be released in the coming week. MANAS 1 is a first step in the advancement of artificial intelligence into neuroscience. It aims to translate the electrical language spoken by the brain to the screen. This will have implications for research and diagnosis, as well as access to healthcare.

Published on Feb 23, 2026, at 2:35 PM (IST)

Join our community of over 2 million industry professionals. Subscribe to the Newsletter to receive latest insights and analysis directly to your inbox.

You can now get all the information about ETHealthworld on your mobile!

Continue Reading

HealthNews

Medanta reports Rs1,195 crores in Q4 FY26; net profit jumps 40%.


New Delhi, Global Health Limited, which operates the corporate hospital network, Medanta, reported a 25.3% year-on year (YoY), increase in total income of Rs 1,195 crores for the quarter ending March this year. Ebitda for this period increased by 17.4% to Rs.290 crore and net profit jumped by 39.7% to reach Rs.141 crore as compared to the Rs.101 crore of Q4 FY25. Medanta has added 86 additional beds to its cacity in Q4 – 32 at Patna and 44 in Noida. The company’s average revenue per occupied beds (ARPOB) rose by 4.8 percent YoY to Rs. 66,687. The facility now has 382 beds with 98 ICU beds as well as 14 operating theatres.

The revenue from international patients was Rs. 67 crore, an increase by 22 per cent year-over-year, but a slight decline in the following months due to flight delays during the West Asia conflict. Bed occupancy was at 62.7%, and out-patients increased by 18.7%.


Published on May 15, 2026, at 2:41 PM (IST)

Join the community and join 2M+ other industry professionals. Subscribe to our Newsletter for the latest industry insights & analyses.

You can now get all the information about ETHealthworld on your mobile!

HealthNews

It is not the technology that will differentiate organisations, but rather superior decision-making. It’s the standard. Many large pharmaceutical companies and medical device manufacturers have already digitalised core functions. From CRM platforms to AI, these companies are far ahead of the curve. Prabha sinha, ZS Co-founder observes that the real shift is now not adding more technology, but rather using it more intelligently.


The ROI comes from the impact of digital on customers. “Digital can keep lights on like S, an infrastructure play,” said he. The real return on investment is when digital drives impact for customers.

This shift from infrastructure to impact is reshing the way life sciences organizations think, act and compete. Four engines of impact: From Projects to digital assets

Sinha described four “engines” that are driving the shift away from traditional projects and towards scalable digital impact. “One of the things that you can do with digital is to shift from project teams doing work, to digital assets doing work,” said Sinha.

Before, it could take up to an entire year for major business decisions such as restructuring the sales force in order to launch a new product. Ten years ago, it took six months to research and six more months to implement. The cycle lasted about a full year. Sinha noted. First, the decision-making cycle has been compressed significantly. “Decision-making can either be accelerated, or planning can be merged with execution,” he said. In place of quarterly planning cycles it is now done on the fly. “It’s a continuous rather than discrete process,” said he. First, digital tools help break down silos. Sinha explained that traditionally, in large companies the departments of sales, service and marketing were quite segregated. Now, digital is breaking down these vertical barriers. It was also important to him that centralised be used. He said: “All of this can only be achieved through centralising marketing and sales – the fourth component.” Sinha, who spoke about AI and for customer engagement, said that the top 100 pharmaceutical companies in the US are all doing it. The differences are in the sophistication. But “in terms of helping salespeople and marketers to determine how to allocate resources, this is a universal AI driven activity now.” Around 70% of ZS’s global workforce are based in India. Much of the intellectual properties behind ZAIDYN – the company’s AI-powered platform – is also developed here. Sinha noted that India was not only a cost center, but also a talent hub. Indian teams were increasingly client-facing, and the innovation process is centered in India. “Much innovation… Many of the algorithm programmes are developed in India.” Sinha said that there is a lack of automated bots being used by companies with customers and physicians. In almost all cases, a human is checking what is hpening. “So, I think that trust is best established through people right now.”

Not more technology, but better decisions will drive healthcare’s next le.

Healthcare data volumes continue to grow ridly – from consumer searches and physician queries to millions of sales interactions per year within a single large pharmaceutical company. Sinha explained that the value of understanding patterns between similar doctors, similar decision-makers, and similar hospitals will come through understanding. He claimed that better informational symmetry could reduce wasted products and improve alignment between product needs and patient requirements. Sinha stated, “Three year implementation cycles are not viable.” The technology is changing faster than the companies can implement it.

Platforms, such as ZAIDYN enable organisations to “be up-and-running within weeks, rather than years,” and to connect evolving tools, without having to rebuild their infrastructure with each new technological advancement. The Bottom Line

Healthcare’s next breakthrough will not be achieved by incrementally adopting technology, Sinha believes. “Competitive differentiating will come from superior intelligence in decision making, not just technology deployment,” said Sinha. The technology may provide the tools but the advantage will go to the organisations who transform data into smarter and faster decisions in the healthcare ecosystem.

Published On February 26, 2026 at 3:07 PM (IST)

Join our community of over 2 million industry professionals. Subscribe to the Newsletter to receive latest insights and analysis directly to your inbox.

You can now get all the information about ETHealthworld on your mobile!

Continue Reading

Latest News

Video1 hour ago

OpenAI Chairman's advice for entrepreneurs

OpenAI Chairman Bret Taylor told Rivian CEO RJ Scaringe that entrepreneurs need to spend more time thinking about …

Wall Street pushes to more records as profits keep piling up for US companies Wall Street pushes to more records as profits keep piling up for US companies
Business2 hours ago

Wall Street pushes to more records as profits keep piling up for US companies

Even with worries about expensive oil and high inflation, the U.S. stock market has run to records largely because U.S....

Video2 hours ago

Tourist sues hotel for refusing tap water, loses case

Italy's Supreme Court has ruled that restaurant and hotel owners aren't legally required to serve tap water after a tourist...

Video2 hours ago

Scenes at Crystal Palace winning first ever European trophy. #BBCNews

Video2 hours ago

FTD Brothers cross finish line to end 33-day marathon challenge. #BBCNews

Video2 hours ago

Journey of rescue diver to find Laos cave missing villagers

Video taken by specialist cave diver Norrased Palasing captures the intense mission to locate the missing villagers trapped inside …

Video3 hours ago

Iran targets US air base after US strikes strain ceasefire

US Central Command confirmed that Iran fired a ballistic missile toward Kuwait overnight, which was intercepted. Iran's Islamic …

Video3 hours ago

Tickborne food allergy surging on Martha’s Vineyard

Martha's Vineyard has become a hotspot for food allergies because of tick bites. CNN went to the island to see...

Video3 hours ago

Jill Biden says she thought husband was having a stroke during 2024 debate. #JoeBiden #BBCNews

Video3 hours ago

Disabled people ‘stuck’ in hospital despite being fit to leave, BBC finds | BBC News

Disabled people have told the BBC they are being left in hospital for months after being declared medically fit to...

Trending News

Join Our Newsletter

Stay updated with breaking news and exclusive content.